Paul C Guest

List of Publications by Year in Descending Order

286 papers	5,236 citations	41 h-index	61 g-index
289 ext. papers	6,375 ext. citations	3.8 avg, IF	6.03 L-index

#	Paper	IF	Citations
286	Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials.. *Nutrients*, **2022**, 14,	6.7	11
285	Gender-specific elevation of plasma anthranilic acid in schizophrenia: Protection against glutamatergic hypofunction?. *Schizophrenia Research*, **2022**,	3.6	0
284	Testing the Effects of Cinnamon Extract Supplementation on Inflammation and Oxidative Stress Induced by Acrylamide. *Methods in Molecular Biology*, **2022**, 2343, 179-190	1.4	0
283	Evaluation of Anti-Hepatocellular-Cancer Properties of β-Sitosterol and β-Sitosterol-Glucoside from Indigofera zollingeriana Miq. *Methods in Molecular Biology*, **2022**, 2343, 229-240	1.4	
282	Protocol for Testing the Potential Antioxidant Effects of Curcuminoids on Patients with Type 2 Diabetes Mellitus. *Methods in Molecular Biology*, **2022**, 2343, 371-379	1.4	
281	Testing for Thyroid Peroxidase and Antineuronal Antibodies in Depression and Schizophrenia. *Methods in Molecular Biology*, **2022**, 2343, 203-213	1.4	
280	Impact of Curcumin on Hepatic Low-Density Lipoprotein Uptake. *Methods in Molecular Biology*, **2022**, 2343, 395-400	1.4	0
279	Testing the Physical and Molecular Effects of Nutritional Supplements and Resistance Exercise in Middle-Aged Females. *Methods in Molecular Biology*, **2022**, 2343, 345-360	1.4	
278	Testing the Anti-inflammatory Effects of Curcuminoids in Patients with Colorectal Cancer. *Methods in Molecular Biology*, **2022**, 2343, 319-330	1.4	
277	Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications. *Methods in Molecular Biology*, **2022**, 2343, 19-35	1.4	2
276	Analysis of Cytotoxic Effects of Zerumbone in Malignant Glioblastoma Cells. *Methods in Molecular Biology*, **2022**, 2343, 361-369	1.4	0
275	Evaluation of Antimicrobial and Anticancer Activities of Bouea macrophylla Ethanol Extract. *Methods in Molecular Biology*, **2022**, 2343, 215-228	1.4	1
274	Measuring the Effects of Berberine on Serum Prooxidant-Antioxidant Balance in Metabolic Syndrome. *Methods in Molecular Biology*, **2022**, 2343, 309-318	1.4	0
273	Evaluation of Antidiabetic Properties of Adenosma Bracteosum Bonati Extracts in Mice with Streptozotocin-Induced Diabetes. *Methods in Molecular Biology*, **2022**, 2343, 165-178	1.4	
272	Proteomic Mapping of the Human Myelin Proteome. *Methods in Molecular Biology*, **2022**, 2343, 191-202	1.4	
271	Testing the Effect of Curcumin on Proliferative Capacity of Colorectal Cancer Cells. *Methods in Molecular Biology*, **2022**, 2343, 287-298	1.4	0
270	Changes in leukocytes and CRP in different stages of major depression.. *Journal of Neuroinflammation*, **2022**, 19, 74	10.1	0

269	Identification of difluorinated curcumin molecular targets linked to traumatic brain injury pathophysiology.. *Biomedicine and Pharmacotherapy*, **2022**, 148, 112770	7.5	2
268	Multiplex Technologies in COVID-19 Research, Diagnostics, and Prognostics: Battling the Pandemic. *Methods in Molecular Biology*, **2022**, 3-20	1.4	0
267	Liquid Chromatography-Mass Spectrometry Analysis of Peripheral Blood Mononuclear Cells from SARS-CoV-2 Infected Patients. *Methods in Molecular Biology*, **2022**, 201-211	1.4	
266	Antibody-Based Affinity Capture Combined with LC-MS Analysis for Identification of COVID-19 Disease Serum Biomarkers. *Methods in Molecular Biology*, **2022**, 183-200	1.4	
265	An overview of the human brain myelin proteome and differences associated with schizophrenia. *World Journal of Biological Psychiatry*, **2021**, 22, 271-287	3.8	5
264	Reduced GABAergic neuropil and interneuron profiles in schizophrenia: Complementary analysis of disease course-related differences. *Journal of Psychiatric Research*, **2021**, 145, 50-59	5.2	0
263	Assessing sex differential in COVID-19 mortality rate by age and polymerase chain reaction test results: an Iranian multi-center study. *Expert Review of Anti-Infective Therapy*, **2021**, 1-11	5.5	1
262	Resveratrol as a Probable Multiheaded Treatment Approach for COVID-19.. *Advances in Experimental Medicine and Biology*, **2021**, 1328, 441-446	3.6	1
261	Hepatoprotective Effect of Trehalose: Insight into Its Mechanisms of Action.. *Advances in Experimental Medicine and Biology*, **2021**, 1328, 489-500	3.6	0
260	Antioxidant Effects of Trehalose in an Experimental Model of Type 2 Diabetes.. *Advances in Experimental Medicine and Biology*, **2021**, 1328, 473-480	3.6	0
259	Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases. *Journal of Neuroinflammation*, **2021**, 18, 245	10.1	9
258	The effect of caloric restriction and fasting on cancer. *Seminars in Cancer Biology*, **2021**, 73, 30-44	12.7	8
257	Obesity and Risk of COVID-19 Infection and Severity: Available Evidence and Mechanisms. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 97-107	3.6	3
256	Effects of Curcumin on Depression and Anxiety: A Narrative Review of the Recent Clinical Data. *Advances in Experimental Medicine and Biology*, **2021**, 1291, 283-294	3.6	2
255	Effects of Curcumin and Its Analogues on Infectious Diseases. *Advances in Experimental Medicine and Biology*, **2021**, 1291, 75-101	3.6	2
254	Research in the Middle East into the Health Benefits of Curcumin. *Advances in Experimental Medicine and Biology*, **2021**, 1291, 1-13	3.6	1
253	Curcumin and Piperine in COVID-19: A Promising Duo to the Rescue?. *Advances in Experimental Medicine and Biology*, **2021**, 1327, 197-204	3.6	4
252	New Therapeutic Approaches and Biomarkers for Increased Healthspan. *Advances in Experimental Medicine and Biology*, **2021**, 1286, 1-13	3.6	

251	Depression, Anxiety, and Stress Among Patients with COVID-19: A Cross-Sectional Study. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 229-236	3.6	2
250	Acute Respiratory Distress Syndrome and COVID-19: A Scoping Review and Meta-analysis. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 211-228	3.6	3
249	Relationship Between COVID-19 and Angiotensin-Converting Enzyme 2: A Scoping Review. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 53-68	3.6	2
248	Acute Kidney Injury and Covid-19: A Scoping Review and Meta-Analysis. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 309-324	3.6	11
247	Antidiabetic Properties of Curcumin: Insights on New Mechanisms. *Advances in Experimental Medicine and Biology*, **2021**, 1291, 151-164	3.6	2
246	The 2019 Novel Coronavirus Disease in Pregnancy: A Systematic Review. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 299-307	3.6	7
245	The Worldwide Effort to Develop Vaccines for COVID-19. *Advances in Experimental Medicine and Biology*, **2021**, 1327, 215-223	3.6	2
244	Plasma Anthranilic Acid and Leptin Levels Predict HAM-D Scores in Depressed Women. *International Journal of Tryptophan Research*, **2021**, 14, 11786469211016474	5.6	2
243	How Do We Manage Breastfeeding During the COVID-19 Pandemic?. *Advances in Experimental Medicine and Biology*, **2021**, 1327, 129-137	3.6	0
242	Effect of Curcumin on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review of Randomized Clinical Trials. *Advances in Experimental Medicine and Biology*, **2021**, 1291, 139-149	3.6	0
241	The Clinical Use of Curcumin for the Treatment of Rheumatoid Arthritis: A Systematic Review of Clinical Trials. *Advances in Experimental Medicine and Biology*, **2021**, 1291, 251-263	3.6	2
240	Psychometric Evaluation of Stress in 17,414 Critical Care Unit Nurses: Effects of Age, Gender, and Working Conditions. *Advances in Experimental Medicine and Biology*, **2021**, 1286, 199-212	3.6	1
239	Age-Specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons. *Advances in Experimental Medicine and Biology*, **2021**, 1327, 63-78	3.6	0
238	Deep Learning Analysis in Prediction of COVID-19 Infection Status Using Chest CT Scan Features. *Advances in Experimental Medicine and Biology*, **2021**, 1327, 139-147	3.6	2
237	Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis. *BioMed Research International*, **2021**, 2021, 1901772	3	8
236	Potential Cross-Links of Inflammation With Schizophreniform and Affective Symptoms: A Review and Outlook on Autoimmune Encephalitis and COVID-19. *Frontiers in Psychiatry*, **2021**, 12, 729868	5	3
235	Comparison of the clinical features in open and closed format intensive care units: A systematic review and meta-analysis. *Anaesthesia, Critical Care & Pain Medicine*, **2021**, 40, 100950	3	0
234	Experience in Nutrition Management of Diabetes-Affected COVID-19 Patients. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 69-80	3.6	

233	Cinnamon: A Promising Natural Product Against COVID-19. *Advances in Experimental Medicine and Biology*, **2021**, 1327, 191-195	3.6	2
232	Survey of Immediate Psychological Distress Levels Among Healthcare Workers in the COVID-19 Epidemic: A Cross-Sectional Study. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 237-243	3.6	4
231	Cardiac Injury in COVID-19: A Systematic Review. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 325-333	3.6	5
230	Coronavirus (COVID-19)-Associated Psychological Distress Among Medical Students in Iran. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 245-251	3.6	4
229	A Survey of Psychological Distress Among the Community in the COVID-19 Epidemic: A Cross-Sectional Study. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 253-260	3.6	1
228	Emerging Technologies for the Treatment of COVID-19. *Advances in Experimental Medicine and Biology*, **2021**, 1321, 81-96	3.6	2
227	Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment. *Schizophrenia Bulletin*, **2020**, 46, 363-373	1.3	26
226	Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. *Journal of Proteomics*, **2020**, 224, 103813	3.9	4
225	MK-801 Treatment of Oligodendrocytes as a Cellular Model of Aging. *Methods in Molecular Biology*, **2020**, 2138, 431-447	1.4	1
224	Measurement of a Surrogate Biomarker for Arginine Vasopressin Secretion in Association with Physiometric and Molecular Biomarkers of Aging. *Methods in Molecular Biology*, **2020**, 2138, 251-262	1.4	
223	Proteomic Analysis of Brain Tissue from a Chronic Model of Stress Using a Combined 2D Gel Electrophoresis and Mass Spectrometry Approach. *Methods in Molecular Biology*, **2020**, 2138, 391-406	1.4	
222	Multiplex Analysis of Circulating Hormone Levels in Rat Models of Age-Related Diseases. *Methods in Molecular Biology*, **2020**, 2138, 381-389	1.4	
221	Testing the Effects of Dietary Seafood Consumption on Depressive Symptoms. *Methods in Molecular Biology*, **2020**, 2138, 233-242	1.4	
220	Two-Dimensional Gel Electrophoresis Combined with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Analysis of Eye Lens to Identify Biomarkers of Age-Related Cataract. *Methods in Molecular Biology*, **2020**, 2138, 217-231	1.4	
219	The Impact of New Biomarkers and Drug Targets on Age-Related Disorders. *Methods in Molecular Biology*, **2020**, 2138, 3-28	1.4	
218	Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer's Disease. *Advances in Experimental Medicine and Biology*, **2020**, 1260, 175-191	3.6	13
217	Long-term Health Outcomes Among Survivors Exposed to Sulfur Mustard in Iran. *JAMA Network Open*, **2020**, 3, e2028894	10.4	5
216	A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study. *European Archives of Psychiatry and Clinical Neuroscience*, **2020**, 270, 127-134	5.1	5

215	Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2020**, 101, 109945	5.5	8
214	Liquid Chromatography Tandem Mass Spectrometry Analysis of Proteins Associated with Age-Related Disorders in Human Pituitary Tissue. *Methods in Molecular Biology*, **2020**, 2138, 263-276	1.4	1
213	Proteomic Analysis of Rat Hippocampus for Studies of Cognition and Memory Loss with Aging. *Methods in Molecular Biology*, **2020**, 2138, 407-417	1.4	2
212	Brain Proteomic Analysis on the Effects of the Antidepressant Fluoxetine. *Methods in Molecular Biology*, **2020**, 2138, 419-430	1.4	1
211	Protocol for the Use of the Ketogenic Diet in Preclinical and Clinical Practice. *Methods in Molecular Biology*, **2020**, 2138, 83-98	1.4	3
210	Insulin Resistance in Schizophrenia. *Advances in Experimental Medicine and Biology*, **2019**, 1134, 1-16	3.6	8
209	Biogenesis of the Insulin Secretory Granule in Health and Disease. *Advances in Experimental Medicine and Biology*, **2019**, 1134, 17-32	3.6	5
208	Plasma xanthurenic acid in a context of insulin resistance and obesity in schizophrenia. *Schizophrenia Research*, **2019**, 211, 98-99	3.6	3
207	Perineuronal oligodendrocytes in health and disease: the journey so far. *Reviews in the Neurosciences*, **2019**, 31, 89-99	4.7	7
206	Of Mice, Whales, Jellyfish and Men: In Pursuit of Increased Longevity. *Advances in Experimental Medicine and Biology*, **2019**, 1178, 1-24	3.6	2
205	Metabolic Biomarkers in Aging and Anti-Aging Research. *Advances in Experimental Medicine and Biology*, **2019**, 1178, 247-264	3.6	3
204	Effects on Glial Cell Glycolysis in Schizophrenia: An Advanced Aging Phenotype?. *Advances in Experimental Medicine and Biology*, **2019**, 1178, 25-38	3.6	5
203	The Therapeutic Potential of Ketogenic Diet Throughout Life: Focus on Metabolic, Neurodevelopmental and Neurodegenerative Disorders. *Advances in Experimental Medicine and Biology*, **2019**, 1178, 77-101	3.6	7
202	Proteomic Markers for Depression. *Advances in Experimental Medicine and Biology*, **2019**, 1118, 191-206	3.6	7
201	The Open Field Test for Measuring Locomotor Activity and Anxiety-Like Behavior. *Methods in Molecular Biology*, **2019**, 1916, 99-103	1.4	97
200	Characterization of the Goto-Kakizaki (GK) Rat Model of Type 2 Diabetes. *Methods in Molecular Biology*, **2019**, 1916, 203-211	1.4	6
199	The Forced Swim Test for Depression-Like Behavior in Rodents. *Methods in Molecular Biology*, **2019**, 1916, 75-80	1.4	12
198	The Y-Maze for Assessment of Spatial Working and Reference Memory in Mice. *Methods in Molecular Biology*, **2019**, 1916, 105-111	1.4	189

197	Characterization of the db/db Mouse Model of Type 2 Diabetes. *Methods in Molecular Biology*, **2019**, 1916, 195-201	1.4	12
196	A Rat Eye Lens Model of Cataract Formation. *Methods in Molecular Biology*, **2019**, 1916, 311-318	1.4	
195	The Elevated Plus Maze Test for Measuring Anxiety-Like Behavior in Rodents. *Methods in Molecular Biology*, **2019**, 1916, 69-74	1.4	43
194	Object Burying Test for Assessment of Obsessive Compulsive Behaviors in Mice. *Methods in Molecular Biology*, **2019**, 1916, 81-85	1.4	3
193	Free Dyadic Social Interaction Test in Mice. *Methods in Molecular Biology*, **2019**, 1916, 93-97	1.4	3
192	The Use of Primary Hepatocytes in Assessment of Drug Safety and Toxicity. *Methods in Molecular Biology*, **2019**, 1916, 289-295	1.4	
191	Preparation of Islets from Rat Pancreas and Assessment of Islet Function. *Methods in Molecular Biology*, **2019**, 1916, 223-232	1.4	
190	Characterization of Transplantable Insulinoma Cells. *Methods in Molecular Biology*, **2019**, 1916, 213-222	1.4	
189	The Nest Building Test in Mice for Assessment of General Well-Being. *Methods in Molecular Biology*, **2019**, 1916, 87-91	1.4	5
188	Glucose homeostasis in major depression and schizophrenia: a comparison among drug-naïve first-episode patients. *European Archives of Psychiatry and Clinical Neuroscience*, **2019**, 269, 373-377	5.1	13
187	Mass Spectrometry Profiling of Pituitary Glands. *Methods in Molecular Biology*, **2018**, 1735, 439-447	1.4	1
186	Pulse-Chase Biosynthetic Radiolabeling of Pancreatic Islets to Measure Beta Cell Function. *Methods in Molecular Biology*, **2018**, 1735, 331-341	1.4	
185	Hyperlocomotion Test for Assessing Behavioral Disorders. *Methods in Molecular Biology*, **2018**, 1735, 421-425	1.4	1
184	Point-of-Care Testing and Personalized Medicine for Metabolic Disorders. *Methods in Molecular Biology*, **2018**, 1735, 105-114	1.4	3
183	Nutritional Programming Effects on Development of Metabolic Disorders in Later Life. *Methods in Molecular Biology*, **2018**, 1735, 3-17	1.4	9
182	Studies of Isolated Peripheral Blood Cells as a Model of Immune Dysfunction. *Methods in Molecular Biology*, **2018**, 1735, 221-229	1.4	3
181	Rapid and Easy Protocol for Quantification of Next-Generation Sequencing Libraries. *Methods in Molecular Biology*, **2018**, 1735, 343-350	1.4	2
180	Developmental Origins of Stress and Psychiatric Disorders. *Methods in Molecular Biology*, **2018**, 1735, 47-58	1.4	4

179	2D-DIGE Analysis of Eye Lens Proteins as a Measure of Cataract Formation. *Methods in Molecular Biology*, **2018**, 1735, 427-437	1.4	
178	Identification of Neural Stem Cell Biomarkers by Isobaric Tagging for Relative and Absolute Quantitation (iTRAQ) Mass Spectrometry. *Methods in Molecular Biology*, **2018**, 1735, 467-476	1.4	1
177	Lab-on-a-Chip Device for Rapid Measurement of Vitamin D Levels. *Methods in Molecular Biology*, **2018**, 1735, 477-486	1.4	2
176	A User-Friendly App for Blood Coagulation Disorders. *Methods in Molecular Biology*, **2018**, 1735, 499-504	1.4	3
175	Proteomic Studies of Psychiatric Disorders. *Methods in Molecular Biology*, **2018**, 1735, 59-89	1.4	1
174	Neuropsychiatric Sequelae of Early Nutritional Modifications: A Beginner's Guide to Behavioral Analysis. *Methods in Molecular Biology*, **2018**, 1735, 403-420	1.4	4
173	Multiplex Immunoassay Profiling of Hormones Involved in Metabolic Regulation. *Methods in Molecular Biology*, **2018**, 1735, 449-456	1.4	3
172	Time-Resolved Fluorescence Assays for Quantification of Insulin Precursors in Plasma and Serum. *Methods in Molecular Biology*, **2018**, 1735, 457-465	1.4	
171	Generation of the Maternal Low-Protein Rat Model for Studies of Metabolic Disorders. *Methods in Molecular Biology*, **2018**, 1735, 201-206	1.4	1
170	Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. *European Archives of Psychiatry and Clinical Neuroscience*, **2018**, 268, 129-143	5.1	32
169	Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. *Frontiers in Psychiatry*, **2018**, 9, 209	5	13
168	Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. *Proteomics*, **2018**, 18, e1700270	4.8	2
167	Two-Dimensional Gel Electrophoresis: A Reference Protocol. *Advances in Experimental Medicine and Biology*, **2017**, 974, 175-182	3.6	3
166	Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients. *Advances in Experimental Medicine and Biology*, **2017**, 974, 3-19	3.6	7
165	SILAC Mass Spectrometry Profiling: A Psychiatric Disorder Perspective. *Advances in Experimental Medicine and Biology*, **2017**, 974, 289-298	3.6	1
164	Proteomic Profiling of the Pituitary Gland in Studies of Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 313-319	3.6	1
163	A Selected Reaction Monitoring Mass Spectrometry Protocol for Validation of Proteomic Biomarker Candidates in Studies of Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 213-218	3.6	
162	Development of a User-Friendly App for Testing Blood Coagulation Status in Schizophrenia Patients. *Advances in Experimental Medicine and Biology*, **2017**, 974, 351-360	3.6	1

161	A Two-Dimensional Difference Gel Electrophoresis (2D-DIGE) Protocol for Studies of Neural Precursor Cells. *Advances in Experimental Medicine and Biology*, **2017**, 974, 183-191	3.6	1
160	Application of Multiplex Biomarker Approaches to Accelerate Drug Discovery and Development. *Methods in Molecular Biology*, **2017**, 1546, 3-17	1.4	5
159	The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients. *Methods in Molecular Biology*, **2017**, 1546, 19-35	1.4	6
158	Multiplex Biomarker Approaches to Enable Point-of-Care Testing and Personalized Medicine. *Methods in Molecular Biology*, **2017**, 1546, 311-315	1.4	3
157	Multiplex Biomarker Approaches in Type 2 Diabetes Mellitus Research. *Methods in Molecular Biology*, **2017**, 1546, 37-55	1.4	2
156	Multiplex Single Nucleotide Polymorphism Analyses. *Methods in Molecular Biology*, **2017**, 1546, 143-148	1.4	1
155	Biomarkers and Mental Illness **2017**,		3
154	The Utility of Multiplex Assays for Identification of Proteomic Signatures in Psychiatry. *Advances in Experimental Medicine and Biology*, **2017**, 974, 131-138	3.6	3
153	Identifying Biomarker Candidates in the Blood Plasma or Serum Proteome. *Advances in Experimental Medicine and Biology*, **2017**, 974, 193-203	3.6	10
152	Sequential Co-immunoprecipitation and Immunoblot Approach to Determine Oligomerisation of G-Protein-Coupled Receptors. *Advances in Experimental Medicine and Biology*, **2017**, 974, 237-243	3.6	
151	A Protocol for Producing the Maternal Low-Protein Rat Model: A Tool for Preclinical Proteomic Studies. *Advances in Experimental Medicine and Biology*, **2017**, 974, 251-255	3.6	1
150	Combining Patient-Reprogrammed Neural Cells and Proteomics as a Model to Study Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 279-287	3.6	3
149	Sequential Immunoprecipitation of Secretory Vesicle Proteins from Biosynthetically Labelled Cells. *Advances in Experimental Medicine and Biology*, **2017**, 974, 157-165	3.6	1
148	Generation of the Acute Phencyclidine Rat Model for Proteomic Studies of Schizophrenia. *Advances in Experimental Medicine and Biology*, **2017**, 974, 257-261	3.6	1
147	Proteomic Profiling of Skin Fibroblasts as a Model of Schizophrenia. *Advances in Experimental Medicine and Biology*, **2017**, 974, 305-311	3.6	1
146	Phenotyping Multiple Subsets of Immune Cells In Situ in Formalin-Fixed, Paraffin-Embedded Tissue Sections. *Advances in Experimental Medicine and Biology*, **2017**, 974, 327-338	3.6	1
145	Connecting Brain Proteomics with Behavioural Neuroscience in Translational Animal Models of Neuropsychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 97-114	3.6	4
144	MK-801-Treated Oligodendrocytes as a Cellular Model to Study Schizophrenia. *Advances in Experimental Medicine and Biology*, **2017**, 974, 269-277	3.6	7

143	What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?. *Advances in Experimental Medicine and Biology*, **2017**, 974, 49-67	3.6	
142	Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. *Advances in Experimental Medicine and Biology*, **2017**, 974, 21-48	3.6	20
141	2D Gel Electrophoresis of Insulin Secretory Granule Proteins from Biosynthetically Labelled Pancreatic Islets. *Advances in Experimental Medicine and Biology*, **2017**, 974, 167-174	3.6	3
140	Selective Reaction Monitoring Mass Spectrometry for Quantitation of Glycolytic Enzymes in Postmortem Brain Samples. *Advances in Experimental Medicine and Biology*, **2017**, 974, 205-212	3.6	0
139	Application of iTRAQ Shotgun Proteomics for Measurement of Brain Proteins in Studies of Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 219-227	3.6	4
138	A Clinical Study Protocol to Identify Serum Biomarkers Predictive of Response to Antipsychotics in Schizophrenia Patients. *Advances in Experimental Medicine and Biology*, **2017**, 974, 245-250	3.6	2
137	A Protocol for Generation of a Corticosterone Model of Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 263-268	3.6	
136	Blood Sampling and Preparation Procedures for Proteomic Biomarker Studies of Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 141-147	3.6	2
135	Multiplex Immunoassay Profiling of Serum in Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 149-156	3.6	4
134	Co-immunoprecipitation for Deciphering Protein Interactomes. *Advances in Experimental Medicine and Biology*, **2017**, 974, 229-236	3.6	5
133	Preparation of Peripheral Blood Mononuclear Cells (PBMCs) as a Model for Proteomic Studies of Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 299-303	3.6	4
132	Development of an Assay for Measuring Proprotein-Conversion Activity on a Multiplex Magnetic Bead-Based Array Platform. *Advances in Experimental Medicine and Biology*, **2017**, 974, 321-326	3.6	
131	Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 69-84	3.6	
130	Proteomic Biomarker Identification in Cerebrospinal Fluid for Leptomeningeal Metastases with Neurological Complications. *Advances in Experimental Medicine and Biology*, **2017**, 974, 85-96	3.6	2
129	LC-MS for Qualitative and Quantitative Proteomic Studies of Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 115-129	3.6	1
128	Lab-on-a-Chip Proteomic Assays for Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 339-349	3.6	4
127	Proteomic Approaches to Enable Point-of-Care Testing and Personalized Medicine for Psychiatric Disorders. *Advances in Experimental Medicine and Biology*, **2017**, 974, 363-370	3.6	
126	LC-MS, Multiplex MS/MS, Ion Mobility, and Label-Free Quantitation in Clinical Proteomics. *Methods in Molecular Biology*, **2017**, 1546, 57-73	1.4	31

125	Assessment of Insulin Resistance Among Drug-Naive Patients With First-Episode Schizophrenia in the Context of Hormonal Stress Axis Activation. *JAMA Psychiatry*, **2017**, 74, 968-970	14.5	17
124	Proteomic Differences in Blood Plasma Associated with Antidepressant Treatment Response. *Frontiers in Molecular Neuroscience*, **2017**, 10, 272	6.1	7
123	Blood Bio-Sampling Procedures for Multiplex Biomarkers Studies. *Methods in Molecular Biology*, **2017**, 1546, 161-168	1.4	2
122	Multiplex Sequential Immunoprecipitation of Insulin Secretory Granule Proteins from Radiolabeled Pancreatic Islets. *Methods in Molecular Biology*, **2017**, 1546, 177-185	1.4	1
121	Depletion of Highly Abundant Proteins of the Human Blood Plasma: Applications in Proteomics Studies of Psychiatric Disorders. *Methods in Molecular Biology*, **2017**, 1546, 195-204	1.4	9
120	Simultaneous Two-Dimensional Difference Gel Electrophoresis (2D-DIGE) Analysis of Two Distinct Proteomes. *Methods in Molecular Biology*, **2017**, 1546, 205-212	1.4	2
119	Multiplex Analyses Using Real-Time Quantitative PCR. *Methods in Molecular Biology*, **2017**, 1546, 125-133	1.4	31
118	Multiplex Analysis Using cDNA Transcriptomic Profiling. *Methods in Molecular Biology*, **2017**, 1546, 135-142	1.4	
117	Two Dimensional Gel Electrophoresis of Insulin Secretory Granule Proteins from Biosynthetically-Labeled Pancreatic Islets. *Methods in Molecular Biology*, **2017**, 1546, 187-194	1.4	
116	Neuroimmune biomarkers in schizophrenia. *Schizophrenia Research*, **2016**, 176, 3-13	3.6	79
115	Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. *Brain, Behavior, and Immunity*, **2016**, 52, 178-186	16.6	16
114	The emergence of point-of-care blood-based biomarker testing for psychiatric disorders: enabling personalized medicine. *Biomarkers in Medicine*, **2016**, 10, 431-43	2.3	23
113	Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research. *International Journal of Neuropsychopharmacology*, **2016**, 19,	5.8	29
112	Effect of MK-801 and Clozapine on the Proteome of Cultured Human Oligodendrocytes. *Frontiers in Cellular Neuroscience*, **2016**, 10, 52	6.1	26
111	Sex Differences in Serum Markers of Major Depressive Disorder in the Netherlands Study of Depression and Anxiety (NESDA). *PLoS ONE*, **2016**, 11, e0156624	3.7	41
110	Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia. *Proteomics - Clinical Applications*, **2016**, 10, 442-55	3.1	8
109	Multiplex immunoassay analysis of plasma shows differences in biomarkers related to manic or mixed mood states in bipolar disorder patients. *Journal of Affective Disorders*, **2015**, 185, 12-6	6.6	13
108	Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms. *Psychiatry Research - Neuroimaging*, **2015**, 233, 112-9	2.9	27

107	Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients. *Journal of Psychiatric Research*, **2015**, 60, 40-8	5.2	29
106	Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. *World Journal of Biological Psychiatry*, **2015**, 16, 22-30	3.8	15
105	Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. *Schizophrenia Research*, **2015**, 161, 4-18	3.6	143
104	A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain. *Journal of Proteome Research*, **2015**, 14, 411-21	5.6	24
103	Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical response. *NPJ Schizophrenia*, **2015**, 1, 15050	5.5	14
102	Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. *NPJ Schizophrenia*, **2015**, 1, 15034	5.5	50
101	The protein interactome of collapsin response mediator protein-2 (CRMP2/DPYSL2) reveals novel partner proteins in brain tissue. *Proteomics - Clinical Applications*, **2015**, 9, 817-31	3.1	30
100	Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. *Proteomics - Clinical Applications*, **2015**, 9, 907-16	3.1	13
99	MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia. *Frontiers in Cellular Neuroscience*, **2015**, 9, 180	6.1	31
98	Hippocampal Proteomic and Metabonomic Abnormalities in Neurotransmission, Oxidative Stress, and Apoptotic Pathways in a Chronic Phencyclidine Rat Model. *Journal of Proteome Research*, **2015**, 14, 3174-87	5.6	13
97	Central and peripheral changes underlying susceptibility and resistance to social defeat stress â A proteomic profiling study **2015**, 1, 1-7		12
96	Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome. *Molecular Autism*, **2014**, 5, 4	6.5	48
95	Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. *Schizophrenia Research*, **2014**, 154, 23-9	3.6	137
94	Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. *Progress in Neurobiology*, **2014**, 122, 45-72	10.9	64
93	Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. *Molecular Autism*, **2014**, 5, 38	6.5	26
92	Proteomic analysis of post mortem brain tissue from autism patients: evidence for opposite changes in prefrontal cortex and cerebellum in synaptic connectivity-related proteins. *Molecular Autism*, **2014**, 5, 41	6.5	43
91	Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3 signaling in bipolar patients. *Journal of Affective Disorders*, **2014**, 156, 139-43	6.6	27
90	Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism. *International Journal of Neuropsychopharmacology*, **2014**, 18,	5.8	41

89	Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. *International Journal of Neuropsychopharmacology*, **2014**, 17, 1599-608	5.8	75
88	The need for a comprehensive molecular characterization of autism spectrum disorders. *International Journal of Neuropsychopharmacology*, **2014**, 17, 651-73	5.8	11
87	Identification of a molecular profile associated with immune status in first-onset schizophrenia patients. *Clinical Schizophrenia and Related Psychoses*, **2014**, 7, 207-15	1.6	23
86	Technological advances for deciphering the complexity of psychiatric disorders: merging proteomics with cell biology. *International Journal of Neuropsychopharmacology*, **2014**, 17, 1327-41	5.8	10
85	Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. *Schizophrenia Bulletin*, **2014**, 40, 787-95	1.3	70
84	The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients. *Biomarkers in Medicine*, **2014**, 8, 15-27	2.3	28
83	Proteomics: improving biomarker translation to modern medicine?. *Genome Medicine*, **2013**, 5, 17	14.4	24
82	Identification of protein biomarkers in human serum using iTRAQ and shotgun mass spectrometry. *Methods in Molecular Biology*, **2013**, 1061, 291-307	1.4	5
81	Development of a novel assay for proprotein converting enzyme activity on a multiplex bead-based array system. *Proteomics*, **2013**, 13, 2976-9	4.8	4
80	Identification of an age-dependent biomarker signature in children and adolescents with autism spectrum disorders. *Molecular Autism*, **2013**, 4, 27	6.5	26
79	Identification of altered dipeptidyl-peptidase activities as potential biomarkers for unipolar depression. *Journal of Affective Disorders*, **2013**, 151, 667-672	6.6	14
78	Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies. *Psychoneuroendocrinology*, **2013**, 38, 752-66	5	59
77	Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. *European Neuropsychopharmacology*, **2013**, 23, 1199-207	1.2	47
76	Application of meta-analysis methods for identifying proteomic expression level differences. *Proteomics*, **2013**, 13, 2072-6	4.8	1
75	Affinity depletion of plasma and serum for mass spectrometry-based proteome analysis. *Methods in Molecular Biology*, **2013**, 1002, 1-11	1.4	22
74	Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. *Genome Medicine*, **2013**, 5, 25	14.4	15
73	A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology. *Neuropsychopharmacology*, **2013**, 38, 2532-44	8.7	42
72	Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. *World Journal of Biological Psychiatry*, **2013**, 14, 478-89	3.8	35

71	Challenges in drug target discovery in bipolar disorder. *Expert Opinion on Therapeutic Targets*, **2013**, 17, 565-77	6.4	5
70	Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders. *Translational Psychiatry*, **2013**, 3, e263	8.6	33
69	Testes sanguíneos de biomarcadores para diagnóstico e tratamento de desordens mentais: foco em esquizofrenia. *Revista De Psiquiatria Clinica*, **2013**, 40, 02-09	0.8	8
68	Estudos traducionais de neuropsiquiatria e esquizofrenia: modelos animais genticos e de neurodesenvolvimento. *Revista De Psiquiatria Clinica*, **2013**, 40, 41-50	0.8	4
67	Os efeitos do estresse na funó do eixo hipotalêmico-pituitário-adrenal em indivíduos com esquizofrenia. *Revista De Psiquiatria Clinica*, **2013**, 40, 20-27	0.8	3
66	Explorando o componente inflamatório da esquizofrenia. *Revista De Psiquiatria Clinica*, **2013**, 40, 28-34	0.8	1
65	Distinct molecular phenotypes in male and female schizophrenia patients. *PLoS ONE*, **2013**, 8, e78729	3.7	41
64	Analysis of the rat hypothalamus proteome by data-independent label-free LC-MS/MS. *Proteomics*, **2012**, 12, 3386-92	4.8	10
63	Proteomic analysis of the maternal protein restriction rat model for schizophrenia: identification of translational changes in hormonal signaling pathways and glutamate neurotransmission. *Proteomics*, **2012**, 12, 3580-9	4.8	15
62	Differential phosphorylation of serum proteins reflecting inflammatory changes in schizophrenia patients. *European Archives of Psychiatry and Clinical Neuroscience*, **2012**, 262, 453-5	5.1	8
61	Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. *European Archives of Psychiatry and Clinical Neuroscience*, **2012**, 262, 657-66	5.1	46
60	Clinical use of phosphorylated proteins in blood serum analysed by immobilised metal ion affinity chromatography and mass spectrometry. *Journal of Proteomics*, **2012**, 76 Spec No., 36-42	3.9	16
59	Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls. *Journal of Proteomics*, **2012**, 76 Spec No., 43-55	3.9	65
58	Biomarker discovery in human cerebrospinal fluid: the need for integrative metabolome and proteome databases. *Genome Medicine*, **2012**, 4, 39	14.4	5
57	Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. *World Journal of Biological Psychiatry*, **2012**, 13, 627-32	3.8	43
56	Antipsychotic treatment of acute paranoid schizophrenia patients with olanzapine results in altered glycosylation of serum glycoproteins. *Journal of Proteome Research*, **2012**, 11, 3743-52	5.6	23
55	Molecular validation of the acute phencyclidine rat model for schizophrenia: identification of translational changes in energy metabolism and neurotransmission. *Journal of Proteome Research*, **2012**, 11, 3704-14	5.6	29
54	Blood test for schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, **2012**, 262 Suppl 2, S79-83	5.1	18

53	The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia. *BMC Research Notes*, **2012**, 5, 146	2.3	26
52	Proteomic approaches to unravel the complexity of schizophrenia. *Expert Review of Proteomics*, **2012**, 9, 97-108	4.2	25
51	Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration. *Journal of Proteome Research*, **2012**, 11, 2533-43	5.6	38
50	Comparison of peripheral and central schizophrenia biomarker profiles. *PLoS ONE*, **2012**, 7, e46368	3.7	65
49	Molecular sex differences in human serum. *PLoS ONE*, **2012**, 7, e51504	3.7	24
48	Characterization of the human primary visual cortex and cerebellum proteomes using shotgun mass spectrometry-data-independent analyses. *Proteomics*, **2012**, 12, 500-4	4.8	13
47	To label or not to label: applications of quantitative proteomics in neuroscience research. *Proteomics*, **2012**, 12, 736-47	4.8	52
46	Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection. *Proteomics - Clinical Applications*, **2012**, 6, 297-303	3.1	33
45	Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. *Translational Psychiatry*, **2012**, 2, e87	8.6	132
44	Identification of a biological signature for schizophrenia in serum. *Molecular Psychiatry*, **2012**, 17, 494-502	15.1	175
43	The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus. *Neuropsychopharmacology*, **2012**, 37, 364-77	8.7	45
42	Converging evidence of blood-based biomarkers for schizophrenia: an update. *International Review of Neurobiology*, **2011**, 101, 95-144	4.4	40
41	Abnormalities in metabolism and hypothalamic-pituitary-adrenal axis function in schizophrenia. *International Review of Neurobiology*, **2011**, 101, 145-68	4.4	23
40	The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. *Antioxidants and Redox Signaling*, **2011**, 15, 2067-79	8.4	89
39	Algorithm development for diagnostic biomarker assays. *International Review of Neurobiology*, **2011**, 101, 279-98	4.4	12
38	Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders. *Expert Review of Molecular Diagnostics*, **2011**, 11, 721-33	3.8	11
37	Proteomic technologies for biomarker studies in psychiatry: advances and needs. *International Review of Neurobiology*, **2011**, 101, 65-94	4.4	28
36	Sex-specific serum biomarker patterns in adults with Asperger's syndrome. *Molecular Psychiatry*, **2011**, 16, 1213-20	15.1	111

35	Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. *Molecular Psychiatry*, **2011**, 16, 848-59	15.1	68
34	The need for phosphoproteomic approaches in psychiatric research. *Journal of Psychiatric Research*, **2011**, 45, 1404-6	5.2	12
33	Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. *Psychoneuroendocrinology*, **2011**, 36, 1092-6	5	110
32	Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy. *Proteomics - Clinical Applications*, **2011**, 5, 644-9	3.1	16
31	Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. *Proteomics*, **2011**, 11, 94-105	4.8	70
30	Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. *Proteomics*, **2011**, 11, 495-500	4.8	36
29	Comprehensive two-dimensional liquid chromatography mass spectrometric profiling of the rat hippocampal proteome. *Proteomics*, **2011**, 11, 501-5	4.8	15
28	Characterizing the proteome of the human dorsolateral prefrontal cortex by shotgun mass spectrometry. *Proteomics*, **2011**, 11, 2347-53	4.8	21
27	Characterization of the human serum depletome by label-free shotgun proteomics. *Journal of Separation Science*, **2011**, 34, 1621-6	3.4	32
26	Challenges of introducing new biomarker products for neuropsychiatric disorders into the market. *International Review of Neurobiology*, **2011**, 101, 299-327	4.4	15
25	Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders. *International Review of Neurobiology*, **2011**, 101, 203-38	4.4	25
24	The application of multiplexed assay systems for molecular diagnostics. *International Review of Neurobiology*, **2011**, 101, 259-78	4.4	
23	Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. *Biomarker Insights*, **2010**, 5, 39-47	3.5	119
22	Identification of targeted analyte clusters for studies of schizophrenia. *Molecular and Cellular Proteomics*, **2010**, 9, 510-22	7.6	23
21	Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia. *Journal of Proteome Research*, **2010**, 9, 4476-89	5.6	72
20	Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. *Journal of Proteome Research*, **2010**, 9, 521-7	5.6	67
19	The role of proteomics in depression research. *European Archives of Psychiatry and Clinical Neuroscience*, **2010**, 260, 499-506	5.1	49
18	Metabonomic studies of schizophrenia and psychotropic medications: focus on alterations in CNS energy homeostasis. *Bioanalysis*, **2009**, 1, 1615-26	2.1	12

17	Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. *Journal of Proteome Research*, **2009**, 8, 3284-97	5.6	48
16	Identification of proteomic changes during differentiation of adult mouse subventricular zone progenitor cells. *Stem Cells and Development*, **2007**, 16, 143-65	4.4	18
15	Identification of Proteomic Changes During Differentiation of Adult Mouse Subventricular Zone Progenitor Cells. *Stem Cells and Development*, **2007**, 071004031550001	4.4	
14	Proteomic analysis identifies alterations in cellular morphology and cell death pathways in mouse brain after chronic corticosterone treatment. *Brain Research*, **2006**, 1102, 12-26	3.7	29
13	Identification of differentiating neural progenitor cell markers using shotgun isobaric tagging mass spectrometry. *Stem Cells and Development*, **2006**, 15, 461-70	4.4	29
12	Detection of gender differences in rat lens proteins using 2-D-DIGE. *Proteomics*, **2006**, 6, 667-76	4.8	13
11	Molecular characterization of adult mouse subventricular zone progenitor cells during the onset of differentiation. *European Journal of Neuroscience*, **2006**, 24, 661-75	3.5	42
10	Mechanisms of action of the antidepressants fluoxetine and the substance P antagonist L-000760735 are associated with altered neurofilaments and synaptic remodeling. *Brain Research*, **2004**, 1002, 1-10	3.7	46
9	A proteomic investigation of drug-induced steatosis in rat liver. *Chemical Research in Toxicology*, **2004**, 17, 605-12	4	57
8	Multiplex proteomic analysis by two-dimensional differential in-gel electrophoresis. *Proteomics*, **2003**, 3, 1162-71	4.8	114
7	Alterations of stress related proteins in genetically altered mice revealed by two-dimensional differential in-gel electrophoresis analysis. *Proteomics*, **2002**, 2, 1018-25	4.8	46
6	Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. *Journal of Biological Chemistry*, **2002**, 277, 15482-5	5.4	87
5	Identification and characterization of a truncated variant of the 5-hydroxytryptamine(2A) receptor produced by alternative splicing. *Brain Research*, **2000**, 876, 238-44	3.7	25
4	A PC12 variant lacking regulated secretory organelles: aberrant protein targeting and evidence for a factor inhibiting neuroendocrine gene expression. *Journal of Neurochemistry*, **1999**, 73, 21-30	6	22
3	Endoplasmic reticulum Ca2+ is important for the proteolytic processing and intracellular transport of proinsulin in the pancreatic beta-cell. *Biochemical Journal*, **1997**, 323 (Pt 2), 445-50	3.8	55
2	The post-translational processing and intracellular sorting of carboxypeptidase H in the islets of Langerhans. *Molecular and Cellular Endocrinology*, **1995**, 113, 99-108	4.4	17
1	Molecular heterogeneity and cellular localization of carboxypeptidase H in the islets of Langerhans. *Endocrinology*, **1991**, 129, 734-40	4.8	46